Autres langues TG Therapeutics, Inc.

Actions

TGTX

US88322Q1085

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/05/2024			Varia. 5j.	Varia. 1 janv.
16,48 ^USD	-5,40 %		-0,84 %	-3,51 %

01/05	Wall Street devrait ouvrir en baisse avant la décision de la Fed sur les taux d'intérêt ; les chiffres de l'emploi privé dépassent les prévisions	MT
01/05	Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Small lymphocytic lymphoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	14/05
Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	01/05
TG Therapeutics: Q1 Earnings Snapshot	01/05
Earnings Flash (TGTX) TG THERAPEUTICS Reports Q1 Revenue $63.5M, vs. Street Est of $54.6M	01/05
TG Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results	01/05
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update	30/04
North American Morning Briefing : Investors Brace -2-	29/04
TG Therapeutics Announces Additional Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	19/04
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	18/04
Sector Update: Health Care	18/04
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	18/04
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	18/04
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis	18/04
Tg Therapeutics, Inc. Awards National Contract by the Department of Veterans Affairs for Briumvi as the Preferred Anti-Cd20 for Relapsing Forms of Multiple Sclerosis	18/04
TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	16/04
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	15/04
Tg Therapeutics Insider Sold Shares Worth $351,340, According to a Recent SEC Filing	13/03
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	08/03
TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum	04/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues TG Therapeutics, Inc.

Actions

TGTX

US88322Q1085

Autres langues

Filtres